199 related articles for article (PubMed ID: 14991586)
1. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet.
Nobuto H; Sugita T; Kubo T; Shimose S; Yasunaga Y; Murakami T; Ochi M
Int J Cancer; 2004 Apr; 109(4):627-35. PubMed ID: 14991586
[TBL] [Abstract][Full Text] [Related]
2. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters.
Kubo T; Sugita T; Shimose S; Nitta Y; Ikuta Y; Murakami T
Int J Oncol; 2001 Jan; 18(1):121-5. PubMed ID: 11115548
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters.
Kubo T; Sugita T; Shimose S; Nitta Y; Ikuta Y; Murakami T
Int J Oncol; 2000 Aug; 17(2):309-15. PubMed ID: 10891540
[TBL] [Abstract][Full Text] [Related]
4. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma.
Shimose S; Sugita T; Nitta Y; Kubo T; Ikuta Y; Murakami T
Int J Oncol; 2001 Sep; 19(3):585-9. PubMed ID: 11494040
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
6. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
[TBL] [Abstract][Full Text] [Related]
7. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
8. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
Sakakibara T; Chen FA; Kida H; Kunieda K; Cuenca RE; Martin FJ; Bankert RB
Cancer Res; 1996 Aug; 56(16):3743-6. PubMed ID: 8706018
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
11. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
[TBL] [Abstract][Full Text] [Related]
12. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
14. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
16. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
17. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
19. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy.
Kono K; Nakashima S; Kokuryo D; Aoki I; Shimomoto H; Aoshima S; Maruyama K; Yuba E; Kojima C; Harada A; Ishizaka Y
Biomaterials; 2011 Feb; 32(5):1387-95. PubMed ID: 21093041
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
